Finally Time For Investors To Sell? Jefferies Downgrades Advaxis (NASDAQ:ADXS), With $2.0000 Target

June 13, 2018 - By Peter Erickson

Advaxis, Inc. (NASDAQ:ADXS) Logo

Investors sentiment increased to 1.14 in 2018 Q1. Its up 0.02, from 1.12 in 2017Q4. It improved, as 10 investors sold Advaxis, Inc. shares while 18 reduced holdings. 9 funds opened positions while 23 raised stakes. 16.99 million shares or 11.99% more from 15.17 million shares in 2017Q4 were reported.

California State Teachers Retirement Sys owns 58,649 shares for 0% of their portfolio. Art Limited Liability Com holds 29,842 shares. Germany-based Deutsche Bank & Trust Ag has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Moreover, Geode Capital Mngmt Limited Liability Corp has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). State Board Of Administration Of Florida Retirement invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Bnp Paribas Arbitrage has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Manufacturers Life Ins Company The holds 0% or 2,136 shares. Tiaa Cref Invest Management Lc holds 0% or 99,999 shares in its portfolio. Moreover, California Employees Retirement Sys has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). State Of Wisconsin Investment Board invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Vanguard Group Incorporated holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 2.10M shares. 24,000 were accumulated by Pnc Group Inc. Tower Ltd Liability Corporation (Trc), New York-based fund reported 10,718 shares. 2,259 were reported by National Bank Of Montreal Can. Parametric Port Assocs Ltd Llc accumulated 26,432 shares or 0% of the stock.

Since December 29, 2017, it had 0 insider purchases, and 3 selling transactions for $20,259 activity. On Friday, February 2 the insider LOMBARDO ANTHONY A sold $94. Another trade for 5,224 shares valued at $16,612 was made by Bonstein Sara on Friday, December 29.

Advaxis (NASDAQ:ADXS) Receives a Downgrade

New York-listed Advaxis (NASDAQ:ADXS), was cut by professional analysts at Jefferies who cut their rating on the $88.40 million market cap firm to a Hold, but decided to stick with their target of $2.0000 on ADXS shares.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis has $23.0 highest and $300 lowest target. $4’s average target is 138.10% above currents $1.68 stock price. Advaxis had 4 analyst reports since December 27, 2017 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Overweight” rating and $5 target in Tuesday, March 13 report. The rating was maintained by H.C. Wainwright on Friday, June 8 with “Buy”. As per Wednesday, December 27, the company rating was maintained by H.C. Wainwright. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Wednesday, March 14 by H.C. Wainwright.

The stock decreased 8.70% or $0.16 during the last trading session, reaching $1.68. About 1.36 million shares traded or 113.43% up from the average. Advaxis, Inc. (NASDAQ:ADXS) has declined 79.31% since June 14, 2017 and is downtrending. It has underperformed by 91.88% the S&P500.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes technology based immunotherapies in the United States. The company has market cap of $88.40 million. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. It currently has negative earnings. The firm is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens.

More notable recent Advaxis, Inc. (NASDAQ:ADXS) news were published by: Businesswire.com which released: “Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach …” on June 11, 2018, also Seekingalpha.com with their article: “Early-stage study of Advaxis’ cancer candidate ADXS-NEO underway” published on June 11, 2018, Seekingalpha.com published: “Advaxis Inc. (ADXS) CEO Ken Berlin on Q2 2018 Results – Earnings Call Transcript” on June 07, 2018. More interesting news about Advaxis, Inc. (NASDAQ:ADXS) were released by: Seekingalpha.com and their article: “Has A New Advaxis Awakened Out Of The Doldrums?” published on June 08, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” with publication date: June 13, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.